Haematologica
HAEMATOL/2016/158394
Version 3

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Amir T. Fathi, Seth A. Wander, Traci M. Blonquist, Andrew M. Brunner, Philip C. Amrein, Jeffrey Supko, Nicole M. Hermance, Amity L. Manning, Hossein Sadrzadeh, Karen K. Ballen, Eyal C. Attar, Timothy A. Graubert, Gabriela Hobbs, Christelle Joseph, Ashley M. Perry, Meghan Burke, Regina Silver, Julia Foster, Meghan Bergeron, Aura Y. Ramos, Tina T. Som, Kaitlyn M. Fishman, Kristin L. McGregor, Christine Connolly, Donna S. Neuberg, and Yi-Bin Chen

Disclosures: The authors would like to report the following conflicts. A.T.F. has participated on advisory boards for Seattle Genetics, Agios, Merck, and Baxalta, providing consulting for Seattle Genetics and Celgene, and receives grant support from Takeda, Celgene, Exelixis, and Seattle Genetics to conduct clinical trials. E.C.A. is employed by Agios Pharmaceuticals. Y.C. receives grant support from Bayer/Onyx to conduct clinical trials. All other authors have no relevant conflicts of interest to declare.

Contributions: A.T.F. developed the study design, performed data collection, and wrote the manuscript; S.A.W. performed data analysis and helped write the manuscript; T.M.B. performed bio-statistical analysis of data; A.M.B. helped in the writing of the manuscript; P.C.A. helped with study accrual and edited the final manuscript; J.S. performed pharmacokinetic analysis; A.L.M. and N.M.H. performed correlative laboratory analysis; H.S. helped with data collection and edited the final manuscript; K.K.B., E.C.A., T.A.G., and G.H. helped with study accrual and edited the final manuscript; C.J., A.M.P., M.B., R.S., J.F., M.B., A.Y.R., T.S.T., K.M.F., K.L.M, and C.C. helped with sample collection, data entry and analysis, and edited the final manuscript; D.S.N. performed bio-statistical analysis of data; Y.C. helped with study design and development, and edited the final manuscript.